Molson Coors Beverage Company

source: coverage-next-full ticker: TAP step: 01 title: Business Model & Overview retrieved: 2026-05-28

Step 01 — Business Model

1. Objective

Describe Molson Coors Beverage Company's business model: what it sells, to whom, through which channels, at what unit economics, and how it converts brand equity into cash.

2. Approach

Used 10-K segment descriptions, IR press releases, the brand portfolio cataloged from FY2025 filings, and competitive context from the industry overview file [S1][S2][S3].

3. Findings

What TAP Sells

A portfolio of beer and beyond-beer beverages spanning value, premium, above-premium, and non-alcoholic categories.

Core power brands (mass-premium light beer, mass-premium lager):

• Coors Light, Miller Lite, Coors Banquet (US)
• Molson Canadian, Coors Original (Canada)
• Carling (UK — largest-volume UK lager)
• Ožujsko (Croatia)
• Staropramen (Czech Republic / Central Europe — flagship)

Above-premium / premium portfolio:

• Blue Moon (US — Belgian-style wheat)
• Leinenkugel's Summer Shandy (US — seasonal)
• Madri Excepcional (UK — Spanish-style lager, now #2 UK on-premise lager by value [S3])
• Peroni Nastro Azzurro (UK distribution — note: TAP holds UK rights; Asahi owns Peroni globally)
• Pilsner Urquell (Central Europe heritage)

Beyond Beer (FMBs, hard seltzers, energy, mixers):

• Topo Chico Hard Seltzer (Coca-Cola JV, US)
• Simply Spiked (Coca-Cola JV, US)
• ZOA Energy (Dwayne Johnson minority-stake partnership)
• Fever-Tree US distribution (exclusive from Feb 1, 2025; 8.5% equity stake) [S4]
• Blue Run Spirits (acquired 2023; partial impairment 2025)

Value brands:

• Miller High Life, Keystone Light (US — value tier)

To Whom

• ~80% of revenue from Americas (US the dominant geography + Canada + LatAm)
• ~20% from EMEA&APAC (UK + Central/Eastern Europe primarily; small Asia presence) [S2]
• B2B customer base: independent beer distributors (US three-tier system), national grocery & C-store chains, on-premise bar/restaurant accounts. End-consumer is the eventual drinker; immediate customer is the distributor / retailer.

Through Which Channels

• Off-premise (grocery, C-store, club, drug): ~75–80% of US volume; price-elastic; competitive shelf-share battles
• On-premise (bars, restaurants, stadiums): ~20–25% of US volume; higher per-unit margin; brand-equity reinforcement role
• Three-tier system (US): Brewer → independent distributor → retailer. Distributors are TAP's economic moat partners — long contracts, geographic exclusivity, mutual investment in tap handles, signage, merchandising. The "12,000 new tap handles" cited post-Bud-Light shift is a distributor-investment metric [S3].

Unit Economics (FY2025 GAAP, with underlying flagged)

Value-Chain Layer Map

How It Makes Money

• Volume × Price × Mix model. Per-hectoliter net sales revenue (NSR/HL) is the master KPI. Volume declines have been offset for several years by pricing + mix shift (above-premium gaining mix share within a contracting overall pie).
• Net pricing 2025: in the +2% to +4% range across regions, with Americas +3–4% and EMEA&APAC +4–5% (constant currency) [S6]. Underlying EBITDA margin held ~21–22% on a 4% decline in net sales — pricing discipline.
• Beyond Beer is partnership-led and capital-light vs. building from scratch. Coca-Cola JV provides marketing reach for Topo Chico + Simply Spiked. Fever-Tree gives TAP the US non-alc-mixer beachhead at minority equity cost.

4. Risks & Counter-Evidence

• Distributor concentration risk: TAP depends on independent distributors. If a major distributor pivots commitment, share losses follow rapidly. The Bud-Light story cuts both ways — TAP captured share via distributor-channel choice, and could lose it via the same mechanism.
• Brand fade risk on light beer: Coors Light and Miller Lite are in a sub-category (mass-premium American light) facing the worst demographic + GLP-1 headwinds. Even with share gains, the addressable pie is shrinking.
• Beyond Beer is small: Despite headlines, beyond beer is a small fraction of revenue. Blue Run Spirits already partially impaired ($75.3M in Q3 2025). Topo Chico Hard Seltzer has not become the share leader many expected.

5. Decision / What I'm doing differently

Treat TAP as a brewer first, beyond-beer aspirant second. ~95% of the equity value comes from the core beer P&L. Beyond-beer is option value — meaningful for the multi-year story but not material to base-case 2026–2028 forecasts.

6. Open Questions

1. Will Madri-style above-premium creations work in the US, or is it a UK-specific phenomenon? Step 03 examines revenue mix evolution.
2. What is the actual unit-economics of the Coca-Cola JV — is TAP economics or marketing-and-distribution-only? Press releases not fully transparent.

7. Source Index

• [S1] TAP_financials/sec_filings/filing_inventory.md — FY2025 10-K
• [S2] TAP_financials/industry/competitive_landscape.md
• [S3] Fox Business — "Coors Light, Miller Lite combined sales now 50% bigger than Bud Light"
• [S4] BusinessWire — Fever-Tree partnership PR (Jan 30, 2025)
• [S5] TAP_financials/xbrl/xbrl_summary.md
• [S6] Molson Coors IR — Q4 2025 / FY2025 earnings release (Feb 18, 2026)

source: coverage-next-full ticker: TAP step: 04 title: Financial Snapshot & Adversarial Research Sweep retrieved: 2026-05-28

Step 04 — Financial Snapshot

1. Objective

Assess the quality of TAP's reported financials, identify accounting / one-time / impairment adjustments, and run the Adversarial Research Sweep for short-seller reports, investigations, lawsuits, and quality-of-earnings flags.

2. Approach

Cross-referenced the cached XBRL summary [S1], reviewed FY2025 impairment disclosures [S2], scanned for litigation / short reports / investigations [S3][S4], and benchmarked GAAP-vs-underlying reconciliation against company-disclosed methodology [S2].

3. Findings

Statement Quality — GAAP vs Underlying

The biggest single quality issue is the FY2025 impairment package: $3,645.7M Americas goodwill + $198.6M Staropramen brand + $75.3M Blue Run Spirits = $3,919.6M aggregate non-cash charges [S2]. All flow through GAAP operating income and to the GAAP net loss of $2,140M.

Underlying basis (company's preferred framing): excludes these impairments + restructuring charges + mark-to-market on commodity hedges + special items. Underlying EBITDA FY2025 ~$2.4B, underlying EPS ~$5.40 (consensus tracking estimate).

Quality verdict: GAAP loss is a true non-cash hit — equity book value reduced by ~$3.9B — but underlying cash-generative business is intact. For analytical purposes, use underlying figures for run-rate earnings power; use GAAP for full disclosure / equity-value-book-discipline check.

Cash Flow Conversion

[S1]

Cash conversion is consistently in the 70–80%+ range of underlying EBITDA — high-quality, well-correlated with reported underlying earnings.

Working Capital Discipline

[S1]

TAP runs negative working capital (payables > receivables + inventory) — typical for CPG with distributor-led downstream financing. No red flags; payables-driven cash management is stable.

Capex Discipline

Capex roughly tracks D&A — no aggressive growth-investment cycle; mostly maintenance + can-line modernization. 2026 guide $650M (also near D&A).

Capital Structure Quality

• Long-term debt $3.81B (2025) — down from $6.06B in 2024 (refinancing / paydown / reclassification effect; some moved to current liabilities — current liab jumped to $5.31B from $3.05B reflecting near-term maturities)
• Net debt $5.4B (per company), 2.3x underlying EBITDA — below stated target of <2.5x [S2]
• Investment-grade credit ratings (BBB / Baa2 area)
• Manageable maturity ladder

Adversarial Research Sweep

Short-seller reports: No active major short-seller report on TAP identified [S3][S4]. Hindenburg, Muddy Waters, Citron, Spruce Point: no published TAP coverage in recent years.

Litigation: Standard product-liability tail risk + ordinary-course commercial disputes; no material outstanding litigation flagged in FY2025 10-K beyond routine.

Regulatory investigations: None disclosed [S2][S3].

Quality-of-earnings flags:

1. Goodwill impairment trigger: The $3.65B Americas goodwill impairment in Q3 2025 was the principal QoE event. Triggered by softer-than-expected current-year results + lower long-term forecasts post-impairment-test [S2]. The market read this as honest reset of accounting carrying value vs. underlying operations.
2. Blue Run Spirits impairment ($75.3M, Q3 2025) — acquired 2023; growth target missed. Small relative to the package; signal: M&A discipline imperfect.
3. Staropramen partial impairment ($198.6M, Q3 2025) — softer CEE volumes; brand-equity reset.

Cash-EPS bridge: Underlying EPS ~$5.40 vs underlying FCF/share ~$5.40 (FCF $1,068M ÷ ~199M shares). They reconcile cleanly. No "earnings-without-cash" issue.

Revenue recognition / channel stuffing: Beer industry is volume-disclosed (HL shipped) — relatively hard to manipulate via revenue-recognition tricks. Distributor-channel inventory is monitored; TAP has not been flagged for channel-stuffing.

Pension / OPEB: Minor relative to size; no acute funding issue disclosed.

Hedge accounting: TAP uses commodity hedges (aluminum, barley, natural gas) and FX hedges. 2025 underlying-vs-GAAP reconciliation includes mark-to-market on non-designated hedges. Standard practice; not a red flag.

Adjusted Free Cash Flow Quality

Underlying FCF (using underlying definitions): roughly $1.0–1.1B annually 2024–2026. 2026 guide $1.1B ± 10% [S5]. This is the truest measure of capacity to fund dividend + buyback + de-leveraging.

4. Risks & Counter-Evidence

• Underlying-vs-GAAP gap is large in 2025 — management has flexibility in defining "underlying" — analyst should track quarter-by-quarter what adjustments are added and ensure they're truly non-recurring.
• Brand impairment risk continues: If US volumes decelerate further, ANOTHER goodwill impairment leg is possible (Americas goodwill now down to $1.95B vs $5.6B at YE2024; smaller cushion but not gone).
• Tax rate: 22–24% underlying ETR is consistent; no aggressive tax-planning red flag.

5. Decision / What I'm doing differently

Use underlying basis for forward modeling. Apply a conservative haircut to underlying EBITDA forecast (10–15%) in the bear case to account for the possibility of further impairments or unfavorable adjustment reclassifications. GAAP results in 2025 are not predictive of run-rate earnings power.

6. Open Questions

1. Will Q3 2026 (impairment-test annual cycle) trigger another non-cash charge? Watch volumes and pricing through H1 2026.
2. How does the $450M cost program show up in adjusted vs GAAP — will restructuring charges be excluded from underlying (the typical "add-back-then-take-credit" pattern)?

7. Source Index

• [S1] TAP_financials/xbrl/xbrl_summary.md
• [S2] Molson Coors Q3 2025 10-Q and 8-K; FY2025 10-K
• [S3] Web search — short-seller report scan (no major TAP coverage from Hindenburg/Muddy Waters/Citron/Spruce Point in trailing 3 years)
• [S4] WSJ / FT / Reuters litigation databases — no material flagged
• [S5] Molson Coors 2026 guidance — Feb 18, 2026 8-K

source: coverage-next-full ticker: TAP step: 12 title: Analyst Debate — Bull vs Bear retrieved: 2026-05-28

Step 12 — Analyst Debate (Bull vs Bear)

Note: transcripts were not loaded (coverage-next-full path). The debate framing is reconstructed from filings, press releases, prepared-remarks summaries in third-party coverage, consensus notes (Barclays UW $43, UBS $45, consensus PT $51.47), and recent news flow rather than from listening to management Q&A.

1. Objective

Frame the active investment debate on TAP and resolve to a Bull Case + Bear Case structure that feeds /complete-coverage Step 15 (scenarios) and the public /stocks/{ticker} page.

2. Approach

Distilled the multi-source evidence package built across Steps 00–11 into the two competing narratives institutional investors actually argue today.

3. The Debate Structure

The active argument is NOT "Bud Light windfall persists" (that's historical context now). The live debate is:

Bulls argue: TAP is a deep-value capital-return story. Trading at 5.7x EV/EBITDA, 8.9x forward P/E, with a 4.7% dividend yield + ~4.6% buyback yield = ~9% shareholder yield. Underlying earnings power is stable around $5.40 EPS even in a category-decline environment; the $450M cost program adds upside; the Bud-Light-era share gains are durable; the Q1 2026 beat shows the cost program is flowing through. At sub-$45/share, you're getting paid a 9% yield to wait while management compounds underlying earnings flat-to-up.

Bears argue: The category is in structural decline that capital return + cost cuts cannot offset. US beer volumes -6% in 2025; -6 to -9% guided for Q2 2026; GLP-1 + cannabis + spirits substitution are accelerating; the Q3 2025 $3.92B impairment was a forced acknowledgment that prior forecasts were too optimistic; residual $1.95B Americas goodwill can be impaired further; 96% FCF payout leaves no buffer; ROIC is barely above WACC; family-controlled dual-class governance limits take-out optionality. Forward EPS guide of -11 to -15% YoY is the floor, not the ceiling. At 5.7x EV/EBITDA there's no "cheap" cushion if the next leg of category decline is -8% rather than -4%.

4. Bull Case — 3 bullets

• 9%+ Total Shareholder Yield Is the Compounding Engine. Combined ~4.7% dividend yield + ~4.6% buyback yield = ~9% combined shareholder yield, fully funded by $1.0–1.1B run-rate FCF. With 5% annual share-count reduction at current pace ($650M/yr buyback at sub-$50 share price), per-share underlying EPS grows ~5% annually even at flat underlying earnings. Forward total return math (9% yield + 5% EPS growth from buybacks) of ~14% is achievable with no underlying earnings growth — the base case for the equity does not require the category to recover, only to stabilize. [S1][S2]

• The $450M Cost Program + Premiumization Provides Operating Leverage Upside. The Feb 2026 announced three-year cost program ($450M cumulative, beginning H2 2026) targets supply-chain productivity, organizational optimization, and plant rationalization (including a UK brewery closure). If even ~$150M flows to net underlying EBITDA by 2028, that's ~6% margin improvement on a flat top line. Concurrently, above-premium portfolio (Madri +15% Q3 2025, Peroni +25% Q3 2025) is climbing toward management's ~33% revenue-mix target from ~27% today. Both together = a multi-year operating-margin expansion runway that current 5.7x EV/EBITDA does not price in. Q1 2026 EPS beat ($0.62 vs $0.38 consensus, +24% YoY) on -2.9% volume is the early proof point that the program is working. [S3][S4]

• Bud-Light-Era Share Gains Are Durable + Modelo Risk Is Already Priced. Coors Light + Miller Lite combined US retail dollars are now ~50% bigger than Bud Light, with 80%+ retention of post-controversy share gains [S5]. CEO Goyal (since Oct 2025) inherited a structurally improved US share position and is doubling down with premium-portfolio investment. While Modelo (STZ) continues to take category-level share, TAP trades at ~5.7x EV/EBITDA vs STZ at ~14x — a ~60% discount that prices in the structural disadvantage and then some. Mean reversion to even ~7x EV/EBITDA (still well below STZ) implies ~30–40% upside on multiple alone, on top of the 9% shareholder yield. [S6]

5. Bear Case — 3 bullets

• The Category Is in Structural Decline, Not a Cyclical Trough. US beer volumes -6% in 2025 [S7]; Q2 2026 US financial volumes guided -6 to -9% YoY [S3]; cannabis beverages projected $2.8B by 2028 at ~17% CAGR [S8]; ~12.5% of US adults have used GLP-1s, with ~43% of cutters reducing beer [S9]; younger cohorts drink materially less than prior generations. There is no plausible scenario in which US beer volumes return to growth this decade. Pricing power (+2–3% annually) is partially exhausted — Q3 2025 impairment was the forced GAAP acknowledgment that prior forecasts were too optimistic, and the remaining $1.95B Americas goodwill is at further risk if 2026 volume tracks the -6 to -9% guide. Even a "stable" thesis assumes -3 to -5% perpetual category decline, with TAP's mass-premium light beer brands in the worst-affected sub-segment.

• 2026 Profit Warning Is the Floor, Not the Ceiling — Underlying EPS -11% to -15% Guided. Feb 18, 2026 guidance: underlying IBT -15% to -18%, underlying EPS -11% to -15% [S3]. Driver mix is unfavorable — aluminum / Midwest Premium tariff inflation is a 100–200 bps gross margin hit, restructuring charges flow through 2026–2027, interest expense steps up on refinancings. Cost program savings are back-half-2026-loaded and may under-deliver (history of CPG cost programs is mixed). If volumes deteriorate beyond guide, the EPS trajectory becomes -15 to -20%, not -11 to -15%, and dividend coverage stretches uncomfortably. 96% FCF payout ratio leaves no margin of error — a $200M shortfall in FCF forces a moderation of buyback pace, removing the share-count tailwind that anchors the bull EPS math.

• Governance Limits Optionality, Multiple Cannot Re-Rate Without a Catalyst. Family-controlled dual-class voting trust (Pentland + Coors) means activist pressure, take-out scenarios, and strategic split-ups are essentially off the table. Berkshire Hathaway does NOT hold TAP per Q1 2026 13F-HR [S10] — removes a common "smart-money-buying" narrative. New CEO Goyal is an internal candidate (24-year tenure) signaling continuity, not strategic reset. Cheap stays cheap absent a re-rating catalyst — and the catalyst path is narrow: another category leg lower could compress the multiple further (5.7x to 4.5x), while a stabilization narrative may take 4–6 quarters of data to credentialize with the market. The 9% shareholder yield is real but could be a value trap if the underlying earnings power steps down by 15–20% from here on top of further multiple compression.

6. Resolution / What I'm doing differently

The two cases are roughly symmetric around the current ~$42 price. The Bull case implies $55–65 fair value (1.3–1.5x current); the Bear case implies $30–35 fair value (0.7–0.8x current). The probability-weighted view is slightly bullish on a 12–24 month horizon (60% bull / 40% bear weighting, given Q1 2026 beat + cost-program credibility), with the 9% yield providing material downside protection in the bear case.

Position-sizing implication (developed in Step 18): small-to-medium tactical/yield position, NOT a core compounder. Right-sized for ~3–5% portfolio weight, with the option to add on category-stabilization data points (Q2 + Q3 2026 prints) or trim on accelerated category decline.

7. Open Questions

1. Does Q2 2026 (Jul–Aug 2026) print confirm Q1 momentum, or revert to the Q1–Q3 2025 weakness?
2. Does the aluminum / Midwest Premium pressure ease into 2027, allowing margin recovery?
3. Does a Bud Light recovery dent TAP's retained share gains, or does Modelo continue taking from both?

8. Source Index

• [S1] TAP_financials/xbrl/xbrl_summary.md — capital return data
• [S2] TAP_financials/other/stockanalysis_summary.md — dividend yield, EV/EBITDA
• [S3] Molson Coors IR — Q4 2025 / FY2025 release (Feb 18, 2026); 2026 guidance
• [S4] Molson Coors Q1 2026 release (Apr 30, 2026); StockStory Q1 CY2026 coverage
• [S5] Fox Business — Coors Light + Miller Lite vs Bud Light
• [S6] TAP_peer_universe.md — multiples vs peers
• [S7] thedrinksbusiness.com — IWSR US alcohol -5% 2025
• [S8] mgmagazine.com — Cannabis Drinks Surge
• [S9] EY — GLP-1 alcohol market dynamics
• [S10] 13Radar / Seeking Alpha — Berkshire Q1 2026 13F-HR (TAP not held)